A Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380
A Randomized, Double-blind, Placebo-controlled, Sequential, Multiple Ascending Dose (MAD) Study Following Oral Administration in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380
A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.
調査の概要
詳細な説明
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C.
Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg.
The next higher dose cohort will be enrolled only after the prior dose cohort has been discharged from the CPC on Day 17 and the SRC has reviewed all available safety/tolerability, PK/PD, and thyroid function data.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Mary Purucker, MD
- 電話番号:1733 +1-240-673-0500
- メール:mary.purucker@pharmaron-us.com
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- Pharmaron Clinical Pharmacology Center (CPC), Inc.
-
コンタクト:
- Mary Purucker, MD
- メール:mary.purucker@pharmaron-us.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
The participant provided signed and dated informed consent.
-
Male or female aged 18-65 years (inclusive).
-
Fasting LDL-C >110 mg/dL (2.85 mmol/L) at screening.
-
Female participants must meet one of the following:
- Postmenopausal status confirmed by follicle-stimulating hormone (FSH) testing, or
- Surgically sterile (medically documented), or
- If with childbearing potential, the participant must agree to use at least one highly effective contraceptive method in combination with an additional effective contraceptive method from study initiation until 3 months after the last dose, or
- Complete abstinence (if agreed by the participant).
Male participants, even if surgically sterilized (e.g., vasectomy), must:
- Use effective barrier contraception and refrain from sperm donation throughout the study and for 3 months after the last dose, or
- Complete abstinence (if agreed upon by the participant). Refer to Section 9.4 for detailed contraceptive requirements.
-
Normal renal function (estimated glomerular filtration rate [eGFR] ≥ 80 mL/min/1.73 m², calculated using the CKD-EPI equation).
-
Good general health, as judged by the Investigator based on: medical/surgical history, complete physical examination, vital signs, laboratory tests, and 12-lead ECG results (all findings either normal or with no clinically significant abnormalities).
-
No significant medical history; assessed to be in good general health at screening, with evaluations completed ≤ 28 days before the first dose.
-
Willingness and ability to: Understand and comply with study procedures/restrictions, complete the trial as planned and communicate effectively with the Investigator.
Exclusion Criteria:
-
Individuals with special dietary requirements unable to comply with standardized diets.
-
Females who are pregnant or lactating, those with pregnancy plans within 3 months post-trial, or female participants with positive pregnancy tests during screening/baseline periods.
-
Participants with febrile illness or active infection within 7 days prior to the first dose of the investigational drug.
-
Participants with positive urine drug screening results.
-
Participants with a history of drug/substance abuse within 5 years prior to the trial or positive drug screening at Day -1.
-
Participants receiving lipid-lowering therapy or with LDL-C > 190 mg/dL, or those with a history of coronary artery disease, cardiac arrhythmias, unexplained syncope, or family history of sudden cardiac arrest.
-
Participants with a history of QTc prolongation:
- QTcF ≥ 450 ms during screening;
- Hypocalcemia or family history of long QT syndrome;
- Use of QT/QTc-prolonging medications;
- ECG abnormalities deemed clinically significant by the Investigator.
-
Tobacco or nicotine product use within 3 months prior to screening or during the study until discharge.
-
Use of other investigational drugs within 40 days prior to enrollment or within ≥ 5 half-lives (whichever is longer).
-
Positive infectious disease screening results during screening (HIV antibody, HBsAg, HCV antibody).
-
Clinically significant laboratory abnormalities per Investigator judgment during screening.
-
Presence of clinically significant hypertension, defined as systolic blood pressure (SBP) > 145 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, at Screening or Admission.
-
Blood loss > 50 mL within 40 days or > 500 mL within 56 days prior to dosing.
-
Regular alcohol consumption (> 1 unit/day) within 1 month prior to screening or positive alcohol test at screening or admission. [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]. Alcohol consumption within 48 hours predose or during CRU stays.
-
Prescription/OTC medication use within 14 days prior to admission (Day -1) or ≥ 5 half-lives (whichever is longer); or use of any of the inhibitors or induces as listed in Appendix 1, CYP3A-, p-glycoprotein- (p-gp) or breast cancer resistance protein (BCRP)-modulating substances (e.g., herbs, grapefruit) within 14 days predose or ≥ 5 half-lives.
-
Thyroid disease history or clinically significant thyroid test abnormalities.
-
Hypersensitivity to thyroid medications.
-
Conditions potentially affecting drug ADME (e.g., gastrectomy, cholecystectomy, inflammatory bowel disease).
-
Clinically significant comorbidities (e.g., GI, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular diseases) that may compromise study conduct/interpretation or pose risks per Investigator assessment.
-
Hypersensitivity to investigational drug components, specific allergy history (asthma, urticaria, eczema), or atopic predisposition (allergy to ≥ 2 drugs/foods like milk/pollen).
-
Any condition deemed by the Investigator to jeopardize participant safety or study integrity.
-
Abnormal thyroid function tests (total/free T3, total/free T4, TSH) beyond reference ranges during screening.
-
Troponin > ULN during screening or Day -1 periods.
-
Presence of any psychiatric disorder or impaired mental capacity that may compromise the ability to provide informed consent, affect the assessment of efficacy, or impair compliance with the study protocol.
-
Any other condition that, in the opinion of the investigator, may jeopardize the safety of the subject or compromise the quality of the clinical study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:MAD Cohort 1: CS060380 1.0 mg
CS060380 1.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions. |
CS060380 is administered orally once daily (QD) Matching placebo is administered orally once daily (QD)
他の名前:
|
|
実験的:MAD Cohort 2: CS060380 2.0 mg
CS060380 2.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions. |
CS060380 is administered orally once daily (QD) Matching placebo is administered orally once daily (QD)
他の名前:
|
|
実験的:MAD Cohort 3: CS060380 4.0 mg
CS060380 4.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions. |
CS060380 is administered orally once daily (QD) Matching placebo is administered orally once daily (QD)
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse Events during the study period
時間枠:Baseline to Day28
|
To characterize the safety and tolerability of multiple doses of CS060380 in healthy participants |
Baseline to Day28
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cmax
時間枠:Day1
|
Pharmacokinetics: Maximum concentration during a dosing interval |
Day1
|
|
Tmax
時間枠:Day1 Day17
|
Pharmacokinetics: Time to maximum plasma concentration |
Day1 Day17
|
|
t1/2
時間枠:Day1
|
Pharmacokinetics: Terminal elimination half-life |
Day1
|
|
AUClast
時間枠:Day1
|
Pharmacokinetics: AUC from time 0 to the last measurable concentration |
Day1
|
|
AUCinf
時間枠:Day1
|
Pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity |
Day1
|
|
CL/F
時間枠:Day1
|
Pharmacokinetics: apparent total plasma clearance |
Day1
|
|
Cmax,ss
時間枠:Day14
|
Pharmacokinetics: steady-state maximum plasma concentration |
Day14
|
|
Cmin
時間枠:Day14
|
Pharmacokinetics: minimum concentration during a dosing interval |
Day14
|
|
t1/2,ss
時間枠:Day14
|
Pharmacokinetics: steady-state terminal elimination half-life |
Day14
|
|
AUCτ (τ = 24 hours)
時間枠:Day14
|
Pharmacokinetics: AUC from time 0 to 24 hours after dosing |
Day14
|
|
CL/Fss
時間枠:Day14
|
Pharmacokinetics: steady-State apparent total plasma clearance |
Day14
|
|
DF
時間枠:Day14
|
Pharmacokinetics: degree of fluctuation |
Day14
|
|
Cavg
時間枠:Day14
|
Pharmacokinetics: mean plasma concentration during a dosing interval |
Day14
|
|
Rac_AUCτ
時間枠:Day14
|
Pharmacokinetics: accumulation ratio based on area under the plasma concentration-time curve |
Day14
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
LDL-C
時間枠:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: low-density lipoprotein cholesterol |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
HDL-C
時間枠:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
Pharmacodynamics: high-density lipoprotein cholesterol |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
|
TG
時間枠:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: triglycerides |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
TC
時間枠:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: total cholesterol |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
SHBG
時間枠:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
Pharmacodynamics: sex hormone binding globulin |
Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
|
|
Total/free T3
時間枠:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
To explore the effects on thyroid function parameters of CS060380 |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
|
total/free T4,
時間枠:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
To explore the effects on thyroid function parameters of CS060380 |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
|
TSH
時間枠:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
To explore the effects on thyroid function parameters of CS060380 |
Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
|
協力者と研究者
捜査官
- 主任研究者:Mary Purucker, MD、Pharmaron Clinical Pharmacology Center (CPC), Inc.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CS060380-MASH-US-I-05
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。